

RCPath Forum: Rapid Genomic Testing for Cancer Patients

24 November 2025, The Royal College of Pathologists, 6 Alie Street, London E1 8QT

Programme

Time	Session	
8.30 - 9.00	Registration (ground floor)	
	Tea and coffee (Elizabeth Foyer)	
Time	Topic – scene setting Chaired by Professor Sarah Coupland, RCPath Registrar	Speaker
9.00 - 9.05	Welcome	Professor Sarah Coupland, RCPath Registrar
9.05 - 9.15	Demographics First survey- baseline opinions	Helen Bentley, Partner, Digital Strategy, Innovation & Experience Design Ernst & Young
9.15 - 9.20	The Future of Pathology	Dr Bernie Croal, RCPath President
9.20 - 9.50	NHSE Genomics perspective	Jane Starczynski, NHS England, Heart of England NHS Foundation Trust Dr Matthew Evans, University
		Hospitals Birmingham NHS Foundation Trust Dr Angela Hamblin, Oxford University Hospitals NHS
		Foundation Trust
9.50 -10.05	NHS Clinical Cancer/ oncology perspective	Dr David Gilligan, Cambridge University Hospitals
10.05 10.20	Pathologist's perspective	Dr David Moore, UCH NHS Foundation Trust
10.20-10.35	Pharmaceutical industry perspective	Dr Janet Valentine PhD, ABPI
10.35-10.50	Cancer patient's perspective	Lorraine Dallas, Roy Castle Foundation SPEAKING REMOTELY
10.50-11.00	Second survey – reflections from scene setting	Helen Bentley, Partner, Digital Strategy, Innovation & Experience Design Ernst & Young





Bronze





BREAK: 11:00 - 11:30 - Tea, Coffee etc. Elizabeth Foyer

Time	Topic - Alternative Approaches Chaired by Professor Peter Johnston, RCPath Vice President for Workforce and Corporate Engagement	Speaker
11.30-11.45	Local Targeted PCR testing	Dr Maria Arcila, Memorial Sloan Kettering Cancer Center
11.45-12.00	Local Targeted NGS testing	Dr Mark Ewalt, Memorial Sloan Kettering Cancer Center
12.00 -12 15	Liquid Biopsy	Sian Morgan, RCPath Genomics SAC Chair
12.15-12.30	Cancer Genomic testing in the USA	Dr Tara Love, Roche Diagnostics
12.30-12.45	Cancer Genomic testing in Australia	Professor Paul Waring, RCPath Special Advisor on Industry Engagement
12.45- 12.50	Third survey – considering options	Helen Bentley, Partner, Digital Strategy, Innovation & Experience Design Ernst & Young
12.50 – 12.55	Briefing for breakout group discussions	Dr Michael Eden, RCPath Clinical Director of Safety and Quality
		Helen Bentley, Partner, Digital Strategy, Innovation & Experience Design Ernst & Young

LUNCH: 12:55 – 13:30 – Hot buffet lunch served in Elizabeth Room foyer



Thank you to our sponsors:



Gold



Silver





Bronze



Time	Topic - Exploring Options Chair: Dr Michael Eden, RCPath Clinical Director of Safety and Quality	Spokesperson
13.30-14.30	On site breakout group discussions	All attendees
13.30-14.30	Virtual breakout group discussions	Virtual attendees
14.30-14.35	Gp 1 report – "Quick for the Sick" testing	Elected by group
14.35-14.40	Gp 2 report – Testing for the "Waiting well"	Elected by group
14.40-14.45	Gp 3 report – Integrating biomarkers	Elected by group
14.45-14.50	Gp 4 report – Tissue vs liquid biopsy	Elected by group
14.50-14.55	Gp 5 report – Workforce training	Elected by group
14.55-15.00	Gp 6 report – Clinical trial screening	Elected by group
15.00-15.25	Discussion – Chaired by Dr Michael Eden	all
15.25-15.30	Fourth survey – identifying solutions	Helen Bentley, Partner, Digital Strategy, Innovation & Experience Design Ernst & Young

BREAK - 15:30 - 16:00 - Tea, Coffee etc. Elizabeth foyer

Time	Topic – Consensus-seeking Chaired by Helen Bentley and Professor Peter Johnston	Speaker
16.00-16.35	Group consensus discussions – chaired by Helen Bentley	all
16.35-16.40	Call for consensus	Professor Peter Johnston, RCPath Vice President for Corporate Engagement and Workforce
16.40 – 16.45	Final survey – participant opinion on the consensus-seeking exercise	Helen Bentley, Partner, Digital Strategy, Innovation & Experience Design Ernst & Young
16.45-16.50	Al - generated consensus	Elliott Young, eMeeka Ltd
16.50-17.00	Closing remarks and next steps	Professor Sarah Coupland, RCPath Registrar

Thank you to our sponsors: Platinum

Gold

Silver

Bronze





